University of Washington: Lymphoma trials
The registry lists 18 Lymphoma studies with University of Washington as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 7Phase 2 12No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
- Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
- Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaTerminatedNCT03269552Phase 2Results posted
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT03023046Phase 2Results posted
- Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
- Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT02489123Phase 2Results posted
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
- Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaCompletedNCT01165112Phase 1/2Results posted
- Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
- Vorinostat in Patients With Primary Cutaneous T-Cell LymphomaTerminatedNCT00958074Phase 2Results posted
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
- Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04852822
- Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
- Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenCompletedNCT02129049Not applicable
- Interleukin-2 in Treating Patients With Mycosis FungoidesCompletedNCT00002687Phase 1